Composition:
Each 1g contains Ciprofloxacin Hcl Monohydrate 3.5mg equivalent to Ciprofloxacin 3mg.
Indications:
Adults and children 1 year and above:
For the treatment of the following infections when known or suspected to be caused by ciprofloxacin-susceptible bacteria, corneal ulcers, conjunctivitis, blepharitis.
Contraindications:
• Hypersensitivity to the active substance or to any of the excipients.
• Hypersensitivity to quinolones.
Dosage and Administration:
Adults and children 1 year and above:
The recommended dosage regimens for adults (including the elderly) and children over the age of one year of age are as follows:
Use in elderly:
Clinical studies have indicated dosage modifications are not required for the elderly.
Use in children:
Safety and effectiveness of Ciprofloxacin eye Ointment was determined in 192 children between the ages of one to 12 years. No serious adverse event was reported in these patients.
Use in hepatic and renal impairment:
No studies have been performed using Ciprofloxacin eye Ointment in patients with kidney or liver problems.
Warnings:
Undesirable effects
Common: corneal deposits, ocular discomfort, ocular hyperaemia.
Uncommon: keratopathy, punctate keratitis, corneal infiltrates, photophobia, visual acuity reduced, eyelid oedema, blurred vision, eye pain, dry eye, eye swelling, eye pruritus, lacrimation increased, eye discharge, eyelid margin crusting, eyelid exfoliation, conjunctivaloedema, erythema of eyelid.
Rare: ocular toxicity, keratitis, conjunctivitis, corneal epithelium defect, diplopia, hypoesthesia eye, asthenopia, eye irritation, eye inflammation, hordeolum.
Interactions:
Specific drug interaction studies have not been conducted with ophthalmic Ciprofloxacin.
Given the low systemic concentration of ciprofloxacin following topical ocular administration of the product, drug interactions are unlikely to occur.
If more than one topical ophthalmic medicinal product is being used, the medicines must be administered at least 5 minutes apart. Eye ointments should be administered last.
Pregnancy:
No clinical data from well-controlled studies in pregnant women are available.
It is preferable to avoid the use of Ciprofloxacin during pregnancy, unless the therapeutic benefit is expected to outweigh the potential risk to the fetus.
Breastfeeding:
Orally administered ciprofloxacin has been found in human breast milk. It is unknown whether ciprofloxacin is excreted to human milk following topical ocular administration. A risk to the suckling child cannot be excluded. Therefore, caution should be exercised when Ciprofloxacin Eye Ointment is administered to a nursing woman.
Effects on ability to drive and use machines:
This product has no or negligible influence on the ability to drive or use machines.
Temporarily blurred vision or other visual disturbances may affect the ability to drive or use machines. If transient blurred vision occurs upon instillation, the patient must wait until the vision clears before driving or using machinery.
Overdose:
A topical ocular overdose of Ciprofloxacin eye Ointment may be rinsed from the eye(s) with lukewarm tap water.
Due to the characteristics of this preparation no toxic effects are to be expected with an ocular overdose of this product, or in the event of accidental ingestion of the contents of one tube.